Olanib 150 mg (Olaparib) is a PARP inhibitor indicated for BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. It prevents cancer cells from repairing damaged DNA, leading to cell death. Common side effects include nausea, anemia, fatigue, and decreased blood cell counts. https://oncomedicure.com/product/olanib-150-mg-olaparib/